Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

AOD9604 | Preclinical Adipocyte and Rodent-Model Literature Review

Research Use Only Notice: This article is intended only for qualified laboratory research personnel working in controlled institutional research settings. It summarizes published preclinical, in-vitro, and analytical research information for research-context interpretation only. It does not provide instructions for human use, personal use, non-research preparation, dosing, administration, application, or any medical or veterinary purpose. All comparisons discussed below are limited to laboratory cell models and standardized laboratory animal model systems.

AOD9604 is a synthetic 16-amino-acid peptide related to the C-terminal region of human growth hormone (hGH), commonly described in analytical literature as an hGH 177–191-related fragment with an additional tyrosine residue at the N-terminus.[1] AOD9604 should be distinguished from unmodified hGH C-terminal fragments and from longer naturally occurring hGH-derived sequences; this distinction should be preserved in laboratory documentation to avoid sequence-level or material-identity misidentification.

AOD9604

For the free-base record (PubChem CID 71300630), AOD9604 is listed with the molecular formula C78H123N23O23S2 and an average molecular weight of 1,815.1 g/mol (monoisotopic/exact mass approximately 1,813.86 Da).[2] The intramolecular disulfide bridge between Cys7 and Cys14 is integral to the peptide’s identity: the PubChem IUPAC representation specifies the oxidized (7→14)-disulfide form, and lot records should confirm the exact disulfide connectivity, counterion, and identity against this reference rather than treat the material as a linear reduced peptide.[2]

Salt forms and associated forms of AOD9604 may have different molecular formula and molecular weight entries in public databases. The acetate/acetic-acid-associated PubChem entry (CID 156599045), for example, lists C80H127N23O25S2 and a molecular weight of approximately 1,875.1 g/mol, reflecting the mass contribution of the associated acetate/acetic-acid component.[3]

This is why peptide identity should always be matched to the specific lot form, counterion assignment, and batch documentation rather than inferred from the name alone.

Research Identity Item Laboratory Reference Information
Common research name AOD9604 / AOD-9604
PubChem CID (free base) 71300630
Peptide description hGH 177–191-related peptide with an additional N-terminal tyrosine residue; laboratory records should distinguish the specified AOD9604 material from unmodified hGH C-terminal fragments or longer hGH-derived sequences
Sequence notation YLRIVQCRSVEGSCGF; the PubChem free-base identity corresponds to the oxidized intramolecular Cys7–Cys14 disulfide form, while lot records should confirm the exact disulfide connectivity, counterion, and identity before quantitative research use
Free-base formula C78H123N23O23S2
Free-base molecular weight Approximately 1,815.1 g/mol (average mass for the oxidized/disulfide form); COAs may report monoisotopic or exact mass values around 1,813.86 Da depending on analytical convention
CAS reference 221231-10-3 is commonly associated with the free-base AOD9604 record; salt forms and associated forms should be verified separately in batch documentation
Typical research-grade purity expectation Usually specified by batch COA, commonly not less than 95% or 98% by HPLC area normalization, depending on the supplied research specification. HPLC area purity is not equivalent to peptide content or molecular identity; these are separate analytical determinations.
Storage expectation Lyophilized peptide is generally stored at -20°C or below, dry, protected from light and moisture, unless the batch COA or supplier specification states otherwise
Solubility handling note Solubility is lot-, salt-form-, pH-, and solvent-system-dependent; small-scale laboratory compatibility testing should be documented before analytical use

Scope of This Review

The published research literature on AOD9604 includes analytical characterization, in-vitro metabolism work, adipocyte-related endpoint studies, and standardized laboratory rodent-model experiments. This article provides a narrative review of research-context interpretation points rather than a quantitative meta-analysis.

It discusses the types of comparative information that can be interpreted from preclinical systems: cell-exposure versus vehicle-control conditions, baseline versus post-exposure laboratory endpoints, and cross-model differences between simplified in-vitro systems and whole-organism model systems.

This review intentionally avoids non-research preparation ratios, individual-use instructions, consumer-facing operation steps, or any statement implying suitability for use outside qualified laboratory research. Data from adipocyte cultures or standardized rodent models cannot be converted into human, veterinary, wellness, cosmetic, sports-performance, or personal-use claims.

In-Vitro Adipocyte Lipolysis Endpoints

In adipocyte research, lipolysis refers to the hydrolysis of stored triacylglycerol into glycerol and free fatty acids, making glycerol and non-esterified fatty acid readouts common laboratory endpoints for studying lipid mobilization under controlled cell-culture conditions.[4] For AOD9604-related in-vitro interpretation, these endpoints should be discussed only as cell-model readouts under defined experimental exposure conditions, not as evidence of outcomes in humans or other non-laboratory settings.

The endpoint discussion in this section describes assay-design considerations and mechanistic readouts that may be useful in adipocyte-model research. It should not be read as a claim that AOD9604 has been proven to directly regulate every signaling node discussed below under all experimental conditions.

Glycerol Release

Glycerol release into conditioned medium is frequently used as a quantitative marker of adipocyte lipolysis because it reflects triglyceride breakdown within the assay period. White adipocytes generally have low glycerol kinase activity, so glycerol release is often treated as a relatively direct index of net lipolytic activity compared with NEFA measurements, which may be confounded by cellular re-esterification.

However, glycerol release is still an assay-dependent endpoint rather than an absolute measure of total intracellular lipid fate. When AOD9604-exposed adipocyte systems are compared with vehicle-control systems, any reported difference in glycerol release should be interpreted in the context of cell model, differentiation state, exposure concentration, incubation duration, assay method, and positive-control performance.

To avoid overstatement, single-concentration observations should not be described as a universal peptide effect. A stronger experimental design compares multiple concentration points, includes vehicle controls, and uses a well-characterized positive control, such as isoproterenol for non-selective β-adrenergic activation, to define the dynamic range of the assay system.

Non-Esterified Fatty Acid Mobilization

Non-esterified fatty acid measurements can complement glycerol-release assays because triglyceride hydrolysis releases fatty acid chains along with glycerol. However, fatty acids released during an assay may be re-esterified, oxidized, bound to albumin, or otherwise handled differently depending on the cell model and medium composition, so NEFA values should not be interpreted in isolation.

A glycerol-to-NEFA comparison can provide additional context, but it should be presented as an exploratory metabolic readout rather than a definitive mechanism claim. Any conclusion about intracellular lipid fate requires supporting experimental design, such as time-course sampling, medium composition control, and parallel enzyme or signaling measurements.

cAMP, HSL, and Lipolytic Signaling Context

Hormone-sensitive lipase (HSL) phosphorylation and movement toward lipid-droplet surfaces are established features of stimulated adipocyte lipolysis in many laboratory models, including 3T3-L1 adipocyte systems. HSL is phosphorylated at multiple sites, with Ser563 and Ser660 phosphorylation by PKA being well-characterized events in β-adrenergic-stimulated lipolysis.[5]

Separate 3T3-L1 adipocyte literature also documents HSL translocation from the cytosol to the lipid-droplet surface during lipolytic stimulation, which supports the use of HSL-related readouts as mechanistic context in adipocyte assays.[6]

For AOD9604 specifically, the upstream molecular target should not be stated as definitively established unless the cited study directly identifies that target under the same experimental conditions. A compliant interpretation is that cAMP, HSL phosphorylation, and related lipolytic markers may be useful mechanistic endpoints in adipocyte-model experiments, while the precise pathway relationship should remain limited to what each cited study actually demonstrates.

Standardized Laboratory Rodent-Model Data

Published AOD9604 research includes an obese Zucker rat study that examined metabolic actions of a synthetic lipolytic domain of human growth hormone under a controlled laboratory protocol.[7] Published mouse-model work also evaluated human growth hormone and the AOD9604 fragment in obese mice and β3-adrenergic receptor knockout mice, providing a preclinical basis for comparing model-dependent lipid-metabolism endpoints.[8]

The β3-adrenergic receptor knockout mouse data should be summarized with a differentiated interpretation rather than as simply β3-AR-dependent or β3-AR-independent. In that published model, chronic AOD9604 treatment did not reproduce the body-weight and lipolysis-related changes observed in wild-type mice, suggesting that β3-AR-related adaptation or signaling context is important for those chronic endpoints.

At the same time, acute AOD9604 exposure was reported to increase energy expenditure and fat oxidation in β3-AR knockout mice, indicating that the acute substrate-utilization findings should not be reduced to direct β3-AR agonist activity alone.[8]

These rodent-model findings should be described as standardized laboratory animal model observations only. They should not be rewritten into generalized efficacy statements, personal-use claims, or direct extrapolations to any non-research application.

Adipose-Tissue Depot Comparisons

Rodent metabolic studies may include depot-level measurements such as epididymal, inguinal, or brown adipose tissue mass. When AOD9604-exposed groups are compared with vehicle-control groups, differences between depots should be interpreted cautiously because visceral, subcutaneous, and brown adipose compartments differ in innervation, vascularization, receptor expression, mitochondrial characteristics, and sensitivity to lipolytic stimuli.

Genetic disruption of the β3-adrenergic receptor in mice has been shown to affect fat stores and adrenergic receptor expression patterns in white and brown adipose tissue, supporting the importance of model genotype when interpreting depot-specific metabolic data.[10]

Depot-specific trends are therefore best framed as model-dependent observations.

A compliant sentence would be: “In standardized laboratory rodent models, depot-level adipose endpoints may differ by tissue compartment, experimental schedule, diet model, genotype, and sampling time.” This avoids implying a universal effect outside the controlled model system.

Plasma Lipid and Fatty-Acid Endpoints

Rodent-model lipid panels may include triglycerides, total cholesterol, non-esterified fatty acids, and lipoprotein-related measurements. These endpoints are highly sensitive to feeding state, model strain, diet composition, time of sample collection, and the interval between last experimental exposure and sample collection.

Because acute lipid mobilization and longer-duration tissue-level changes can point in different directions, sample timing is a critical variable. A short-interval sample may capture transient fatty-acid mobilization, while a later sample may reflect a different metabolic state.

Therefore, cross-study comparisons should not be made unless the feeding state, sampling window, model type, genotype, and analytical method are comparable.

Respiratory Exchange Ratio and Substrate Oxidation

Indirect calorimetry uses oxygen consumption and carbon dioxide production to calculate respiratory quotient or respiratory exchange ratio (RER), with values closer to 0.7 generally associated with greater lipid oxidation and values closer to 1.0 generally associated with greater carbohydrate oxidation under suitable steady-state assumptions.[9] In rodent metabolic chambers, RER values can be affected by diet composition, light-dark cycle, activity level, feeding state, stress, chamber acclimation, and sample timing.

For AOD9604-related rodent-model interpretation, lower RER observations should be described only as laboratory calorimetry findings consistent with altered substrate utilization in that model. They should not be converted into broad claims about body composition, personal outcomes, or non-research application.

In-Vitro Versus Rodent-Model Interpretation

A key interpretation issue in AOD9604 research is that in-vitro adipocyte assays and whole-organism rodent models answer different questions. Cell-culture assays allow tighter control of concentration, exposure time, medium composition, and endpoint selection, while rodent models introduce diet, locomotor activity, endocrine state, compensatory physiology, tissue distribution, clearance, and model-specific metabolic background.

The β3-adrenergic receptor pathway is relevant to rodent adipose and energy-balance research. Genetic disruption of the β3-adrenergic receptor in mice has been shown to affect fat stores and adrenergic receptor expression patterns in white and brown adipose tissue, supporting the importance of model genotype when interpreting β-adrenergic-linked metabolic data.[10]

In AOD9604-related mouse-model interpretation, the available β3-AR knockout data are best framed as endpoint-specific: chronic body-weight and lipolysis-related effects observed in wild-type mice were not reproduced in the knockout model, whereas acute energy-expenditure and fat-oxidation effects were still reported in the knockout model.[8]

Accordingly, differences between in-vitro and rodent-model outcomes should not be treated as contradictions by default. They may reflect expected differences between simplified cell systems and whole-organism models, including differences in exposure, clearance, compensatory physiology, tissue distribution, genotype, endpoint selection, and sampling timing.

Material Identity, Purity, and COA Interpretation

For peptide research materials, batch identity and purity should be evaluated through lot-specific documentation. HPLC purity can describe chromatographic area percentage under a specified method, but it does not by itself prove correct molecular identity, salt form, peptide content, biological behavior, or suitability for any non-research purpose.

Mass-spectrometry-based confirmation is particularly important for peptide identity. AOD9604 has been studied using analytical approaches for detection and in-vitro metabolism, and published work has identified potential metabolites after serum and urine incubation under laboratory conditions.[11]

For a research COA, HPLC and MS information should be interpreted together with lot number, appearance, counterion or salt form, water content if reported, residual-solvent information if applicable, storage conditions, and method-specific acceptance criteria. When interpreting MS data, researchers should note the expected monoisotopic mass of approximately 1,813.86 Da for the oxidized free-base form and verify the observed deconvoluted mass against the appropriate reference rather than against the average molecular weight, unless the reporting laboratory explicitly uses average-mass convention.

COA purity data are laboratory raw-material quality-control indicators. They cannot be used to infer human suitability, veterinary suitability, field use, personal use, or non-research effectiveness.

A compliant COA interpretation should state only whether the tested lot meets the stated research-material specification under the analytical methods listed on the document.

Data-Quality Recommendations for Research Interpretation

  • Use model-specific wording. Describe findings as “in-vitro adipocyte model observations” or “standardized laboratory rodent-model observations,” rather than as general biological outcomes.
  • Avoid universal mechanism claims. Where pathway data are incomplete, write “consistent with” or “may be associated with” rather than “proves” or “directly activates.” For AOD9604-related β3-AR knockout data, separate chronic body-weight/lipolysis endpoints from acute energy-expenditure and fat-oxidation endpoints.
  • Report controls and timing. Vehicle controls, positive controls, exposure duration, feeding state, genotype, and sample timing are essential for interpreting lipolysis and lipid-panel data.
  • Separate purity from identity. HPLC purity and MS identity confirmation answer different analytical questions and should not be treated as interchangeable.
  • Distinguish mass conventions. The free-base average MW (approximately 1,815.1 g/mol) and monoisotopic mass (approximately 1,813.86 Da) represent different mass conventions; COA interpretation should match the convention used by the reporting laboratory.
  • Do not extrapolate beyond the model. Preclinical cell and rodent-model data should not be translated into personal, medical, cosmetic, wellness, sports-performance, or veterinary claims.

Research-Only Conclusion

The published preclinical literature on AOD9604 supports discussion of this peptide in laboratory contexts such as analytical-method development, in-vitro metabolism work, adipocyte-model endpoint design, and standardized laboratory rodent-model metabolic studies. The strongest compliant interpretation is that AOD9604-related findings are model-, endpoint-, genotype-, and protocol-dependent, with meaningful differences expected between simplified cell systems and whole-organism laboratory models.

For any research lot, key structural and analytical features to verify include the intact Cys7–Cys14 disulfide bridge, the correct free-base or salt/associated-form molecular weight, and the specified 16-amino-acid identity. For responsible research communication, AOD9604 content should remain limited to laboratory context, cite specific authoritative sources for peptide identity and experimental claims, avoid unsupported absolute conclusions, and clearly separate raw-material quality-control data from any non-research implication.

Research Use Only Disclaimer

Research Use Only: The research-grade materials discussed in this article are intended exclusively for qualified laboratory research purposes and are not approved for human or veterinary use. This guide/article is provided for informational context regarding published laboratory in-vitro/in-vivo research literature only, and does not constitute medical, clinical, veterinary guidance, treatment advice, or instructions for non-research use.